CoChat

Effects of gut microbial therapy on lipid profile in individuals with non-alcoholic fatty liver disease: an umbrella meta-analysis study

Open access
Naghipour, Amirhossein, Amini-Salehi, Ehsan, Orang Gorabzarmakhi, Mahdi, Shahdkar, Milad, Fouladi, Bahman, Alipourfard, Iraj, Sanat, Zahra Momayez · 2023 · Systematic Reviews

The DOI matches its Crossref record; 85 of the 86 references it cites were found in a registry or an index.

Abstract

Background: Non-alcoholic fatty liver disease (NAFLD), the most common liver disease, is closely associated with metabolic conditions such as obesity and diabetes mellitus, which significantly impact human health outcomes. The impaired lipid profiles observed in NAFLD individuals can further contribute to cardiovascular events. Despite the high prevalence of NAFLD, there is currently no confirmed intervention approved for its treatment. This study aimed to summarize the results of meta-analysis studies of randomized control trials assessing the impact of gut microbial therapy (probiotics, synbiotics, and prebiotics) on the lipid profile of individuals with NAFLD. Methods: A systematic search was conducted on PubMed, Scopus, Web of Science, and Cochrane Library up to November 1, 2022. Meta-analyses surveying the impact of microbial therapy on lipid profile parameters (triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and total cholesterol (TC)) in the NAFLD population were included in our umbrella review. The final effect size (ES) was estimated, and sensitivity and subgroup analyses were performed to explore heterogeneity. Results: Fifteen studies were included in this umbrella review. Microbial therapy significantly reduced TG (ES − 0.31, 95% CI − 0.51, − 0.11, P < 0.01), TC (ES − 1.04, 95% CI − 1.46, − 0.61, P < 0.01), and LDL (ES − 0.77, 95% CI − 1.15, − 0.39, P < 0.01) in individuals with NAFLD. However, the effect on HDL was not statistically significant (ES − 0.06; 95% CI − 0.19, 0.07, P = 0.39). Conclusion: Considering the absence of approved treatments for NAFLD and the promising role of microbial therapies in improving the three lipid profiles components in individuals with NAFLD, the use of these agents as alternative treatment options could be recommended. The findings underscore the potential of gut microbial therapy, including probiotics, synbiotics, and prebiotics, in managing NAFLD and its associated metabolic complications. Trial registration: PROSPERO (CRD42022346998). Graphical Abstract:

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13643-023-02299-x

Cites

85 of 85 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Study selection process
Fig. 1 Study selection processCC BY · PubMed Central
Fig. 2 A Forest plot for the effect size and 95% confidential interval of microbial therapy on serum TG level in NAFLD patients. B Results of publication bias with seven imputed studies (red dots)
Fig. 2 A Forest plot for the effect size and 95% confidential interval of microbial therapy on serum TG level in NAFLD patients. B Results of publication bias with seven imputed studies (red dots)CC BY · PubMed Central
Fig. 3 A Forest plot for the effect size and 95% confidential interval of microbial therapy on serum TC level in NAFLD patients. B Results of publication bias with seven imputed studies (red dots)
Fig. 3 A Forest plot for the effect size and 95% confidential interval of microbial therapy on serum TC level in NAFLD patients. B Results of publication bias with seven imputed studies (red dots)CC BY · PubMed Central
Fig. 4 Forest plot for the effect size and 95% confidential interval of microbial therapy on serum HDL level in NAFLD patients (A). B is illustrating the results of publication bias with two imputed studies (red dots)
Fig. 4 Forest plot for the effect size and 95% confidential interval of microbial therapy on serum HDL level in NAFLD patients (A). B is illustrating the results of publication bias with two imputed studies (red dots)CC BY · PubMed Central
Fig. 5 A Forest plot for the effect size and 95% confidential interval of microbial therapy on serum LDL level in NAFLD patients. B Results of publication bias with one imputed study (red dots)
Fig. 5 A Forest plot for the effect size and 95% confidential interval of microbial therapy on serum LDL level in NAFLD patients. B Results of publication bias with one imputed study (red dots)CC BY · PubMed Central
Fig. 6 Mechanism of gut microbiome modulation on lipid profile: 1 Bile salt deconjugation. 2 Increased hepatic LDL receptors. 3 Increased bile salt excretion. 4 Co-precipitation of cholesterol. 5 Assimilation of cholesterol and bile salt into the probiotics cell membrane. 6 Cholesterol reduction. 7 Inhibition of Niemann–Pick C1 like 1 expression. 8 Hepatic synthesis of cholesterol inhibition
Fig. 6 Mechanism of gut microbiome modulation on lipid profile: 1 Bile salt deconjugation. 2 Increased hepatic LDL receptors. 3 Increased bile salt excretion. 4 Co-precipitation of cholesterol. 5 Assimilation of cholesterol and bile salt into the probiotics cell membrane. 6 Cholesterol reduction. 7 Inhibition of Niemann–Pick C1 like 1 expression. 8 Hepatic synthesis of cholesterol inhibitionCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 85 references

Research works printed but not linked: 4

  1. Paschos P, Paletas K. Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia. 2009;13(1):9–19.
  2. Meroni M, Longo M, Dongiovanni P. The role of probiotics in nonalcoholic fatty liver disease: a new insight into therapeutic strategies. Nutrients. 2019;11(11). https://doi.org/10.3390/nu11112642. · DOI · Paper page
  3. Koutnikova H, Genser B, Monteiro-Sepulveda M, et al. Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2019;9(3):e017995. https://doi.org/10.1136/bmjopen-2017-017995. · DOI · Paper page
  4. Xiao MW, Lin SX, Shen ZH, Luo WW, Wang XY. Systematic review with meta-analysis: the effects of probiotics in nonalcoholic fatty liver disease. Gastroenterol Res Pract. 2019;2019:1484598. https://doi.org/10.1155/2019/1484598. · DOI · Paper page

Cited by

See all 37

Metadata

Authors
Naghipour, A., Amini-Salehi, E., Orang Gorabzarmakhi, M., Shahdkar, M., Fouladi, B., Alipourfard, I., & Sanat, Z. M.
Affiliations
  • Kerman University of Medical Sciences (IR)
  • Guilan University of Medical Sciences (IR)
  • Zabol University of Medical Sciences (IR)
  • Institute of Physical Chemistry (PL)
  • Digestive Disease Research Institute (IR)
Corresponding author
Sanat, Zahra Momayez
Venue
Systematic Reviews
Published
2023-08-21
Volume
12
Issue
1
Pages
144-144
ISSN
2046-4053 (ISSN-L)
OpenAlex
W4386033594
Cited by
37
References
86
Citations by year
2026: 3 · 2025: 18 · 2024: 13 · 2023: 3
FWCI
1.45
Type
journal article
Language
en
Open access
Licence
Locations
  • Systematic Reviews (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
Keywords
non-alcoholic fatty liver disease, probiotics, synbiotics, prebiotics, lipid profile, triglycerides, total cholesterol, LDL cholesterol, HDL cholesterol, dyslipidemia, obesity, diabetes mellitus, cardiovascular risk, metabolic complications, complementary and alternative medicine, gut microbiota modulation, dysbiosis
MeSH terms
Gastrointestinal Microbiome, Humans, Lipoproteins, HDL, Meta-Analysis as Topic, Randomized Controlled Trials as Topic, Probiotics, Prebiotics, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of gut microbial therapy on lipid profile in individuals with non-alcoholic fatty liver disease: an umbrella meta-analysis study. https://app.cochat.ai/papers/10.1186/s13643-023-02299-x
The paper
Naghipour, A., Amini-Salehi, E., Orang Gorabzarmakhi, M., Shahdkar, M., Fouladi, B., Alipourfard, I., & Sanat, Z. M. (2023). Effects of gut microbial therapy on lipid profile in individuals with non-alcoholic fatty liver disease: an umbrella meta-analysis study. Systematic Reviews. https://doi.org/10.1186/s13643-023-02299-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.